linjc16/ctgov huggingface dataset:
Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age

Study Overview
=================
Brief Summary
-----------------
With the use of molecular methods new viruses have been detected in respiratory and gastrointestinal tracts of both patients and asymptomatic subjects in recent years. The clinical importance of these viruses has not been adequately studied. The aim of this study is to use molecular methods to detect viruses in upper respiratory tract and gastrointestinal tract of children with acute bronchiolitis, acute gastroenteritis and febrile convulsions and to try to correlate the severity of clinical picture with the amount of viruses present in clinical samples. The investigators will also try to detect the increase in specific antibodies in paired sera.

Official Title
-----------------
Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age - the Clinical Relevance of Newly Discovered Viruses

Conditions
-----------------
Bronchiolitis, Gastroenteritis, Convulsion, Febrile

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of acute bronchiolitis acute gastroenteritis febrile convulsion requiring hospital admission Exclusion Criteria: none

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute bronchiolitis<br>Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation. | |
| Acute gastroenteritis<br>Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study. | |
| Febrile convulsion<br>Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection. | |
| Control group<br>Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the clinical picture of a viral respiratory and/or gastrointestinal infection associated with a specific viral pathogen |  | In a 14-day period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To correlate the severity of clinical picture with the quantity of virus in clinical samples |  | In a 14-day period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute bronchiolitis, acute gastroenteritis, febrile convulsion, viral agents, molecular methods
Injectable Filler for Facial Soft Tissue Augmentation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the safety and performance of Hydroxytite in all subjects who have received sub dermal or deep dermal injections.

Official Title
-----------------
An Open-label, Retrospective, Postmarketing Study of Safety and Performance of Hydroxytite, a Calcium Hydroxyapatite Based Filler for Facial Soft Tissue Augmentation.

Conditions
-----------------
Wrinkles

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is over 18 years of age Patient received Hydroxytite injection(s). Exclusion Criteria: • Patient declines to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety of Hydroxytite (Crystalys) in subjects who received subdermal or deep-dermal injections | Adverse events or Serious adverse events, Injection site reactions. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance | To give a score, using the LRS, to Hydroxytite treatment compared to patient's baseline | 6 months | 
| Performance | To give a score, using the Global Aesthetic Improvement Scale (GAIS), to Hydroxytite treatment compared to patient's baseline | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasolabial folds, Marionette lines, Cheek bones, Jaw lines
The Effect of COVID-19 on Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The study aimed to evaluate the effect of SARS-COV-2 infection on metabolic status in patients with diabetes mellitus. Patients' HbA1c levels before and after SARS-COV-2 infection will be evaluated.

Detailed Description
-----------------
In this time pediods, all patients with RT-PCR positive for SARS-COV-2 will be analysed for the presence of diabetes mellitus. Previous HbA1c levels will be obtained from hospital records. In these patients, previous A1c levels and A1c levels 3 months after the SARS-COV-2 infection will be compared.

Official Title
-----------------
The Effect of COVID-19 on the Glycemic Control in Patients With Diabetes Mellitus

Conditions
-----------------
Diabetes Mellitus, Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All hospitalised diabetic patients with RT-PCR- positive for SARS-COV-2 will be enrolled. Exclusion Criteria: - The absence of diabetes mellitus RT-PCR- negative for SARS-COV-2 Non-hospitalised patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A1c | the change in A1c levels | 6 months (3 months before and after COVID-19 |
Natural Orifice Specimen Extraction in Sigmoid Volvulus

Study Overview
=================
Brief Summary
-----------------
Sigmoid resection can be performed using conventional and laparoscopic methods. There are few publications in the literature reporting specimen removal from the natural hole in patients with a diagnosis of sigmoid volvulus. Here, the investigators aimed to present the literature that transanal specimen removal is a technically feasible method after laparoscopic surgery in patients with sigmoid volvulus.

Detailed Description
-----------------
Sigmoid resection can be performed using conventional and laparoscopic methods. There are few publications in the literature reporting specimen removal from the natural hole in patients with a diagnosis of sigmoid volvulus. Here, the investigators aimed to present the literature that transanal specimen removal is a technically feasible method after laparoscopic surgery in patients with sigmoid volvulus. The documents of patients who were operated on for sigmoid volvulus between 2018 and 2019 were retrospectively reviewed. Patients who had been used transanal for specimen extraction by elective laparoscopic sigmoid colon resection were included in the study. Patients' gender, age, comorbidity, operation time, operative difficulties, complications, length of stay, and mortality findings were analyzed. Laparoscopic sigmoid resection and transanal specimen removal were performed in eight patients. Specimen extraction surgery from the natural hole is increasingly preferred. the investigators think that natural hole surgery can be performed more easily and reliably in sigmoid volvulus due to the large diameter of the colon.

Official Title
-----------------
Natural Orifice Specimen Extraction in Sigmoid Volvulus Patients

Conditions
-----------------
Mortality, Morbidity

Intervention / Treatment
-----------------
* Procedure: Natural Orifice Specimen Extraction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: transanal for specimen extraction by elective laparoscopic sigmoid colon resection Exclusion Criteria: emergency surgery conventional open sigmoid resection conventional laparoscopic sigmoid resection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Natural Orifice Specimen Extraction|Natural Orifice Specimen Extraction via transanal|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | mortality after this procedure | 1 year | 
| morbidity | morbidity after this procedure | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colon, volvulus, natural orifice, laparoscopy, sigmoid
Causes of Non-invasive Fungal Sinusitis as Presented in Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
in this study, the investigators will collect data from patients with non-invasive fungal sinusitis to know what causes it

Detailed Description
-----------------
In this study, the investigators will try to know the epidemiology of noninvasive fungal sinusitis, especially in recurrent cases This study will be carried out at sohag university hospital. Retrospective study Study period: 5 years (from August 2016 to August 2021. )

Official Title
-----------------
Epidemiological Study of Non-invasive Fungal Sinusitis as Presented in Sohag University Hospital

Conditions
-----------------
Sinus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Acute fungal sinusitis. Patients with chronic granulomatous sinusitis. Patients with sinus mycetomas. Exclusion Criteria: Immunocompromised patients. invasive fungal sinusitis.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factors related to non-invasive fungal sinusitis | retrospective study assessed by Statistical Package for Social Sciences | 5 years study period from august 2016 to august 2021 |
The Evaluation of Airway Dimension by Using Ultrasonography

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to measure the dimension of airway in healthy Asian population. We recruit normal volunteer subjects aged more than 20 years old. Subglottic transverse diameter is measured and recorded by ultrasonography.

Detailed Description
-----------------
The aim of this study is to measure the dimension of airway in healthy Asian population. We recruit normal volunteer subjects aged more than 20 years old. Subglottic transverse diameter is measured and recorded by ultrasonography.

Official Title
-----------------
The Evaluation of Airway Dimension by Using Ultrasonography

Conditions
-----------------
Subglottic Airway Diameter in Normal Adults

Intervention / Treatment
-----------------
* Other: assessment of subglottic diameter by ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult healthy volunteers (aged more than 20 years) without pre-existing airway or respiratory diseases, neck tumors and a history of neck operation. Exclusion Criteria: pre-existing airway or respiratory diseases, neck tumors and a history of neck operation.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| transverse glottic diameter by ultrasonography | transverse glottic diameter by ultrasonography | one day |
Predictors of Constipation in Healthy Children

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to see if a questionnaire on bowel habits can help identify children who will have constipation 12 months later.

Detailed Description
-----------------
Constipation in children is a common complaint, accounting for an estimated 3% of all pediatric office visits and 20% of visits to a pediatric gastroenterologist. Unfortunately, constipation can become chronic in many children even before the problem has been recognized by a parent or primary care physician. We have previously characterized the bowel habits of more than 3300 primarily middle class Caucasian children 1 to 8 years of age presenting to their primary care practitioner for a health maintenance visit. However, the validity of information concerning bowel habits of children obtained by recall is not well established. The potential benefit of this study to society will be the demonstration that a bowel habit questionnaire can predict the outcome of clinically important constipation.

Official Title
-----------------
Predictors of Constipation in Healthy Children

Conditions
-----------------
Constipation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presenting for a health maintenance visit

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
constipation, bowel habits
Composition of the Exhaust Gas of Pneumoperitoneum During Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
This research aims to study the composition of the peritoneal exhaust gas during laparoscopic surgery to detect and possibly quantify the presence of air and / or N2O. This purely descriptive work is part of other experimental work that the investigators have already published.

Official Title
-----------------
Qualitative Assessment of the Composition of the Exhaust Gas of Pneumoperitoneum During Laparoscopic Surgery: Prospective Gas Chromatographic Study

Conditions
-----------------
Pneumoperitoneum

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient Patient who will benefit from a laparoscopic surgery at Strasbourg University Hospitals Patient who has consented to the use of her medical data for research purposes. Exclusion Criteria: - Refusal of the patient to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to quantify the composition of the exhaust gas of pneumoperitoneum during laparoscopic surgery by gas chromatography |  | 1 day after laparoscopic surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumoperitoneum, Exhaust gas, chromatographic study, Nitrous oxide, Nitrogen dioxide
IVL for Stent Underexpantsion

Study Overview
=================
Brief Summary
-----------------
The IVL-Dragon Registry was a multicenter study that enrolled consecutive patients with stent underexpansion treated with IVL in high-volume PCI centers. The primary efficacy endpoint was clinical success, defined as a reduction of stent underexpansion to <30% with no evidence of in-hospital device-oriented composite end point (DOCE) (defined as a composite of cardiac death, target lesion revascularization, and target vessel myocardial infarction).

Official Title
-----------------
Intravascular Lithotripsy for the Treatment of Stent Underexpansion: the Multicenter IVL-DRAGON Registry

Conditions
-----------------
In Stent Restenosis, Coronary Artery Calcification, Intravascular Lithotripsy

Intervention / Treatment
-----------------
* Device: Percutaneous Coronary Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stent underexpansion treated with intravascular lithotripsy (IVL) Exclusion Criteria: no
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Percutaneous Coronary Intervention|Intravascular lithotripsy (IVL)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Success | Reduction of stent underexpansion to the value of <30% with no evidence of in-hospital device-oriented composite end point (DOCE) | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DOCE | composite of cardiac death, target lesion revascularization (TLR), target lesion revascularization, (TLR), and target vessel myocardial infarction (MI) | 30 days |
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Study Overview
=================
Brief Summary
-----------------
WVE-HDSNP1-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120101 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism, rs362307 (SNP1). To participate in the study, patients must have completed the Phase 1b/2a clinical study WVE-HDSNP1-001.

Official Title
-----------------
A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's Disease

Conditions
-----------------
Huntington Disease

Intervention / Treatment
-----------------
* Drug: WVE-120101


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: 1. Patient successfully completed the Phase 1b/2a study with WVE-120101, WVE-HDSNP1-001. Key Exclusion Criteria: 1. Received an investigational drug other than WVE-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer. 2. Inability to undergo brain MRI (with or without sedation). 3. Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WVE-120101 (Dose A)<br> | Drug: WVE-120101<br>* WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: Number of Patients With Treatment-emergent AEs (TEAEs) |  | First dose received (Day 1) through the Study Termination visit (maximum of 45 weeks of treatment) | 
| Safety: Number of Patients With a Severe TEAE |  | First dose received (Day 1) through the Study Termination visit (maximum of 45 weeks of treatment | 
| Safety: Number of Patients With Serious TEAEs |  | First dose received (Day 1) through the Study Termination visit (maximum of 45 weeks of treatment | 
| Safety and Tolerability: Number of Patients Who Withdraw Due to TEAEs |  | First dose received (Day 1) through the Study Termination visit (maximum of 45 weeks of treatment |
The Effect of the ALDH2 Gene Polymorphism on the Propofol Potency for Inducing Loss of Consciousness

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether ALDH2 gene polymorphisms (G/G, G/A A/A) have effect on the potency of propofol.

Official Title
-----------------
The Effect of the ALDH2 Gene Polymorphism on the Propofol Potency for Inducing Loss of Consciousness in Cardiac Patients: a Prospective Observational Study

Conditions
-----------------
Propofol

Intervention / Treatment
-----------------
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA II Exclusion Criteria: ASA III-IV OSAS hepatic and renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| G/G group<br>Patients who are determined to be G/G genotype. | Drug: Propofol<br>* Patients will be induced to unconsciousness using propofol intravenously.<br>|
| G/A A/A group<br>Patients who are determined to be G/A or A/A genotypes. | Drug: Propofol<br>* Patients will be induced to unconsciousness using propofol intravenously.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect-site concentration | patient's effect-site concentration when he/she loss consciousness | immediately after patient lose his/her consciousness | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propofol, ALDH2, potency